At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 08 Jul 2008 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 30 Nov 2000 New profile
- 29 Nov 2000 Preclinical development for Thrombosis in USA (Unknown route)